We are live on ! Find out more

Neuraxis

NRXS

Market cap $74.8M

5.96 USD

-0.11

1.81%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

5.95

-0.01

0.17%

1 day

-1.81%

5 days

-0.67%

1 month

-14.98%

3 months

-18.02%

6 months

2.58%

Year to date

33.63%

1 year

142.28%

5 years

-0.67%

10 years

-0.67%

About: Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Employees: 24

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Zacks Investment Research

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

NeurAxis Expands Payer Coverage with New Policies

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.

NeurAxis Expands Payer Coverage with New Policies

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

Zacks Investment Research

NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y

NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.

NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y

NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript

NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth

CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026.

NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, May 12, 2026, at 9:00 am ET to review the results.

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

NeurAxis Expands Payer Coverage with Four New Medical Policies

CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced four additional health insurers with medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 1.25 million covered lives. These medical policies expand incremental access to IB-Stim treatment for beneficiaries in West Virginia, New Hampshire, South Carolina, Virginia, and Florida.

NeurAxis Expands Payer Coverage with Four New Medical Policies

NeurAxis, Inc. Announces Preferred Stock Dividend

CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock.

NeurAxis, Inc. Announces Preferred Stock Dividend

See News Rankings

Price charts implemented using Lightweight Charts™